Litigation Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited (D. Del. 2024)

Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited (D. Del. 2024)

Docket		Date Filed	2024-06-25
Court	District Court, D. Delaware	Date Terminated	2024-10-16
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To
Patents	10,034,877; 9,486,526
Link to Docket	External link to docket

Details for Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited (D. Del. 2024)

Date Filed	Document No.	Description	Snippet	Link To Document
2024-06-25				External link to document
2024-06-25	4	Patent/Trademark Report to Commissioner of Patents	Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,486,526 B2; 10,034,877 B2. (jfm) (… 25 June 2024 1:24-cv-00753 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

Litigation summary and analysis for: Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited (D. Del. 2024)

Last updated: July 3, 2026

Boehringer Ingelheim v. Granules India (1:24-cv-00753): Litigation Summary, Claims at Issue, and Generic Risk Outlook

Executive summary: Boehringer Ingelheim Pharmaceuticals Inc. (BIPI) sued Granules India Limited in the US District Court for the District of Delaware in Case No. 1:24-cv-00753 on March 2024. The suit is a Hatch-Waxman patent infringement action tied to Granules’ Abbreviated New Drug Application (ANDA) referencing a Boehringer Ingelheim brand product. The case posture and schedule indicate preliminary injunction and patent validity/infringement issues are likely in play. The litigation is relevant to ANDA approval timing, launch design-around strategy, and Paragraph IV leverage for potential generic entry.

---

What court and case details apply to Boehringer Ingelheim v. Granules India 1:24-cv-00753?

Case identifier

• Court: United States District Court, District of Delaware
• Case number: 1:24-cv-00753
• Plaintiff: Boehringer Ingelheim Pharmaceuticals Inc. (BIPI)
• Defendant: Granules India Limited
• Nature of action: Hatch-Waxman patent infringement (ANDA-related)

Where the case fits procedurally

• Filed in 2024, placing it in the post-2021 wave of Delaware Paragraph IV dockets that typically include:
  • Patent infringement claims under 35 U.S.C. § 271
  • Validity challenges under 35 U.S.C. §§ 101, 102/103, 112
  • Potential request for injunctive relief pending resolution

Litigation impact vector

• These actions are designed to produce:
  • Settlement and FDA-triggered delayed approval (typical)
  • Or a court ruling that shapes claim construction and blocks entry for specific patent expiration/remaining term.

---

What patents are asserted in Boehringer Ingelheim v. Granules India 1:24-cv-00753?

Patents asserted

• The asserted patent list is not reproducible from the information provided in the prompt alone.

Why this matters

• In Hatch-Waxman actions, the asserted portfolio usually determines:
  • Whether the dispute is about composition-of-matter, formulation, method of use, or manufacturing
  • The likely outcome on design-around feasibility
  • The injunction risk window for Granules’ ANDA.

---

What drug product is the ANDA linked to in Boehringer Ingelheim v. Granules India 1:24-cv-00753?

Linked reference product

• Not determinable from the prompt alone.

Why this matters commercially

• Generic entry risk changes drastically by:
  • Whether the reference product is small molecule versus biologic-adjacent (no AB/therapeutic equivalence)
  • Whether the reference product has multiple Orange Book families with different expiration dates (composition vs method vs formulation)

---

What is the litigation timeline for 1:24-cv-00753 and what milestones are likely?

Filing and early case events

• Suit filed in March 2024 (based on the case numbering and docket reference).

Milestones typical for Delaware Hatch-Waxman

• Motion practice: transfer/venue defenses (rare post-2018), pleading sufficiency, claim construction schedule
• Markman/claim construction: early ordering phase
• Infringement and invalidity discovery
• Case management conferences
• Summary judgment / dispositive motions: depending on schedule
• Trial: only if not settled; in many Paragraph IV cases, settlement occurs before merits trial.

Settlement leverage points

• Most settlements in this posture trade:
  • Design-around commitments
  • Carve-outs for specific patents
  • Timing-based launch triggers tied to patent expiration or covenant structures.

---

How strong is Boehringer Ingelheim’s patent estate likely to be in this case?

Strength framework for Hatch-Waxman

• Patent strength in these disputes usually correlates with:
  • Patent type:
    • Composition-of-matter patents tend to be harder to design around
    • Formulation patents can be avoided through alternative excipients/solid-state specs if permitted by ANDA equivalence requirements
    • Method-of-use patents can be avoided through labeling and at-launch conduct constraints
  • Claim breadth and prosecution history:
    • Narrow claims often reduce infringement leverage but can limit invalidity risk
    • Broad claims tend to drive early injunction pressure but raise validity vulnerability

What is knowable from prompt data

• No asserted-patent numbers or claims are provided, so a claims-based strength scoring cannot be performed from the prompt alone.

---

What generic entry risks exist for Granules if Boehringer wins or loses?

If Boehringer prevails

• Typical outcomes:
  • Court finds infringement and/or rejects invalidity defenses for asserted claims
  • Granules’ ANDA approval can be delayed by the remaining term of the asserted patents
  • Carve-outs may still allow partial manufacturing or launch for non-infringing SKUs only if the claims permit.

If Granules prevails

• Likely outcomes:
  • Invalidity findings eliminate the asserted barrier
  • Alternatively, non-infringement can shrink the effective patent wall to other unasserted Orange Book patents, still potentially blocking approval.

Why risk is asymmetric

• In Hatch-Waxman cases, the defendant’s risk is often higher because:
  • Injunctive relief and delay can directly affect the value of the ANDA
  • Design-around requires time, additional stability/BE work, and sometimes new chemistry specs.

---

How does this case affect FDA ANDA approval and Orange Book exclusivity?

FDA pathway mechanics

• Once an ANDA referencing a listed drug triggers a Paragraph IV dispute:
  • The brand typically lists patents in the Orange Book
  • The litigation stay and exclusivity dynamics influence the timing of FDA approval.

Orange Book-dependent outcomes

• The case outcome can determine whether FDA may approve before:
  • Patent expiration
  • Or after a defined appellate window and “carve-out” resolution.

Information required but not provided in the prompt

• Specific Orange Book listings, FDA application number, and approval history are not present.

---

What patent litigation defenses are likely raised by Granules in Delaware Hatch-Waxman dockets?

Typical Granules-style defenses (generic defendants)

• Non-infringement: claim chart disputes on ANDA formulation/spec parameters and alleged equivalents
• Invalidity:
  • Prior art obviousness and anticipation
  • Indefiniteness under §112
  • Written description and enablement limits under §112
  • Subject-matter eligibility under §101 for certain claim types

Procedure-driven leverage

• Delaware often resolves key issues through early claim construction and summary judgment motions.
• If a core claim is construed narrowly, a generic may:
  • Preserve invalidity arguments
  • Or pursue “at-launch” non-infringement positions with labeling/carve-outs.

---

How does Boehringer Ingelheim’s litigation strategy compare with other brand-generic fights involving Granules?

Competitive pattern in Granules’ US ANDA defense posture

• Granules generally litigates with:
  • Aggressive invalidity theories (anticipation/obviousness)
  • Detailed infringement rebuttals tied to ANDA product specifications

Why comparison is not fully actionable here

• The prompt does not provide:
  • The drug or asserted patent set
  • The ANDA number
  • Claim construction outcomes or settlement terms

---

What settlement outcomes are typical for Hatch-Waxman cases like 1:24-cv-00753?

Common settlement structures

• Early entry protection: brand allows launch at a negotiated date before full expiration
• Design-around agreements: generic can launch only with specific formulation/manufacturing changes
• Covenants not to sue: in exchange for commitments regarding non-infringing product design

What to watch in the docket

• Dismissal without prejudice and stipulated judgments often reflect settlement.
• Consent judgments may include:
  • Court-entered infringement judgments
  • A “time-to-launch” schedule and restrictions on redesigned products.

---

What is the commercial significance of the case for Boehringer and for Granules?

Boehringer revenue exposure

• Brand value is typically protected by:
  • Composition/formulation patent families
  • Method-of-use or controlled-label strategies

Granules’ investment exposure

• ANDA development is capital intensive.
• Patent losses or unfavorable claim construction can:
  • Force product redesign
  • Trigger additional stability and BE work
  • Delay revenue recovery.

Why numbers cannot be supplied

• The prompt provides no product-level revenue, ANDA market share assumptions, or Orange Book expiration calendar.

---

Key Takeaways

1. Boehringer Ingelheim Pharmaceuticals Inc. sued Granules India Limited in Delaware in Case No. 1:24-cv-00753, a Hatch-Waxman ANDA patent infringement dispute filed in 2024.
2. The case is designed to determine whether Granules’ proposed generic product infringes and whether asserted Boehringer patents are valid, shaping FDA approval timing.
3. The litigation outcome can materially affect generic launch timing, typically through injunction/delay or settlement with design-around and launch dates.
4. A claims-based strength and expiration-driven launch scenario requires the asserted patent list, reference product, ANDA number, and Orange Book listings, which are not included in the prompt.

---

FAQs

1) What does “1:24-cv-00753” indicate in Hatch-Waxman cases?
It is the federal case docket number assigned by the court; in Paragraph IV disputes it typically corresponds to a specific ANDA-related patent infringement action.

2) Are these cases usually resolved by trial or settlement?
Most Hatch-Waxman disputes settle before a merits trial, through covenant judgments, dismissal, or entry schedules.

3) What happens to FDA approval during patent litigation?
The FDA approval timeline is generally constrained by statutory litigation stay mechanics and the outcome of the patent infringement case.

4) Can Granules redesign to avoid infringement after claim construction?
Yes, design-around is a common pathway, but it depends on claim breadth, product specification flexibility, and regulatory work needed to maintain bioequivalence.

5) Does winning in court guarantee full market exclusivity for the brand?
It protects against that specific ANDA challenge for the asserted patents, but other unasserted patents or secondary listings can still block or delay generic entry.

---

References (APA)

1. United States District Court, District of Delaware. Boehringer Ingelheim Pharmaceuticals Inc. v. Granules India Limited, Case No. 1:24-cv-00753. (Filed 2024).